Imexpharm Corp 2022 SR
The report highlights Imexpharm's 45th anniversary and its position as a leading pharmaceutical manufacturer in Vietnam with 11 EU-GMP production lines. In 2022, the company achieved a total net revenue of 1,668 billion VND and a pre-tax profit of 291.4 billion VND. Key sustainability achievements include significant reductions in energy and water consumption intensity despite increased production. The company also focused on employee welfare, with average incomes increasing by 15%, and continued its commitment to community education and local startup support.
Company: Imexpharm Corp
Sector: Manufacturing
Country: Vietnam
Year: 2022
Type: SR
Pages: 63
Back to company
Imexpharm Corp
Sustainable Development Report
The report highlights Imexpharm's 45th anniversary and its position as a leading pharmaceutical manufacturer in Vietnam with 11 EU-GMP production lines. In 2022, the company achieved a total net revenue of 1,668 billion VND and a pre-tax profit of 291.4 billion VND. Key sustainability achievements include significant reductions in energy and water consumption intensity despite increased production. The company also focused on employee welfare, with average incomes increasing by 15%, and continued its commitment to community education and local startup support.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Published
Dec 31, 2022
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees